Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ketoconazole
Drug ID BADD_D01230
Description Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981.[A188054] At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue to be used in topical formulations.
Indications and Usage Ketoconazole is used in the treatment or prevention of fungal infections including blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.[FDA Label] In Europe, it is also used in the treatment of endogenous Cushing's syndrome.[L7736]
Marketing Status approved; investigational
ATC Code D01AC08; G01AF11; H02CA03; J02AB02
DrugBank ID DB01026
KEGG ID D00351
MeSH ID D007654
PubChem ID 3823
TTD Drug ID D0B4IF
NDC Product Code 60524-000; 62991-1461; 63629-8677; 68788-8257; 51927-0065; 52286-0009; 35573-433; 43538-531; 50090-6142; 63629-8675; 63629-8819; 70518-0915; 72789-052; 53002-8151; 63629-8820; 71205-105; 68071-2902; 70518-3367; 71085-008; 72189-428; 58159-091; 50090-0720; 51672-1298; 53002-8150; 68071-2309; 59349-0001; 0093-3219; 45802-465; 50090-6069; 63629-8676; 63646-010; 70518-2831; 72189-180; 51407-279; 55505-192; 63187-774; 68788-7755; 49452-3913; 66478-0145; 16714-955; 43538-530; 45802-532; 66267-400; 71713-097; 38779-0279; 53069-0390; 0168-0099; 51672-4026; 64380-827; 68788-9903; 71335-1849; 65085-0028; 50090-5265; 51552-0627; 51927-3194; 68981-023; 55505-196; 60429-020
UNII R9400W927I
Synonyms Ketoconazole | R-41400 | R 41400 | R41400 | R41,400 | Nizoral
Chemical Information
Molecular Formula C26H28Cl2N4O4
CAS Registry Number 65277-42-1
SMILES CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OCC3COC(O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urticaria23.04.02.001; 10.01.06.0010.000290%
Ventricular arrhythmia02.03.04.006--
Visual field defect17.17.01.001; 06.02.07.0030.000066%Not Available
Vomiting07.01.07.0030.000758%
Xeroderma23.01.02.003--Not Available
Mental status changes19.07.01.0010.000132%Not Available
Acute generalised exanthematous pustulosis11.07.01.018; 10.01.01.034; 23.03.10.002; 12.03.01.005--Not Available
Application site vesicles23.03.01.009; 12.07.01.009; 08.02.01.0090.000099%Not Available
Peripheral swelling02.05.04.015; 08.01.03.0530.000257%Not Available
Sudden cardiac death08.04.01.008; 02.03.04.0160.000066%Not Available
Breast discomfort21.05.05.0070.000066%Not Available
Self-injurious ideation19.12.01.007--Not Available
Malignant neoplasm progression16.16.01.0050.000099%Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Application site swelling08.02.01.027; 12.07.01.0270.000066%Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.000224%Not Available
Angiopathy24.03.02.007--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Adverse event08.06.01.0100.000771%Not Available
Breast disorder21.05.04.004--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.000343%
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Blood disorder01.05.01.004--Not Available
Adverse drug reaction08.06.01.0090.000224%Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene